RightFit
RecruitingPhase not listed

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Biospecimen Collection and Donation to the AIDS and Cancer Specimen Resource (ACSR): A Companion Protocol to AMC Trials

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study collects donated blood and tissue to learn how genes and other body factors are linked to HIV-related cancers. It is for adults with HIV and cancer, and some adults without HIV who have certain related cancers. The criteria also mention people with HIV who have a condition that raises their cancer risk.

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You must be at least 18 years old.
  • If you have HIV, the criteria require a cancer diagnosis. They also list conditions that raise your risk of cancer.
  • If you do not have HIV, you must have a new cancer or cancer that has come back with a known scientific link to an AIDS-related cancer.
  • Examples include certain types of Kaposi sarcoma, anal cancer, multicentric Castleman’s disease, and certain lymphomas (cancers of immune system cells).
  • If you have HIV, you need proof from medical records, records of HIV treatment with at least two medicines, or certain HIV tests. HIV prevention medicine (PrEP) alone does not count as proof.
  • The study doctor must decide that you or your legal representative can understand and agree to the study. You or your representative must sign a consent form.

Who can't join

    Simplified for readability. The official criteria below are what the study team uses.

    Official eligibility criteria

    Inclusion Criteria: * Participants must be at least 18 years of age * Participant must be HIV- positive and have a diagnosed malignancy. If participants are HIV-negative, they must have a newly diagnosed or recurrent malignancy that has an established scientific connection (e.g., shared etiology) to an AIDS- associated malignancy such as: * classic Kaposi sarcoma * transplant-associated Kaposi sarcoma, * anal cancer, * multicentric Castleman's disease, * Epstein Barr Virus (EBV) -positive lymphoma * plasmablastic lymphoma * Hodgkin's lymphoma. * For participants that are HIV-positive, HIV infection must be documented by means of any one of the following: : * Documentation of HIV diagnosis in the medical record by a licensed health care provider; * Documentation of receipt of antiretroviral therapy (ART) by a licensed health care provider (Documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name. Receipt of at least two agents is required; each component agent of a multi-class combination ART regimen will be counted toward the 2-agent requirement, excepting receipt of a pre-exposure prophylaxis (PrEP) regimen alone \[e.g., Truvada\], which is exclusionary); * HIV ribonucleic acid (RNA) detection by a licensed HIV RNA assay demonstrating \> 1000 RNA copies/mL; * Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV Western blot confirmation or HIV rapid multispot antibody differentiation assay. * Participants with HIV infection, regardless of participation in an AMC clinical trial, must have a diagnosis of cancer, cancer or a condition that places them at a higher risk of cancer. * The investigator determines that the participant (or his/her legally authorized representative \[LAR\]) has the ability to provide informed consent and the participant or LAR provides written informed consent.

    Study sites (8)

    CA

    DC

    FL

    MD

    NY

    UT